S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke.

BACKGROUND AND PURPOSE Better techniques are needed to monitor infarction volume and predict neurological outcome after ischemic brain infarction. We evaluated the usefulness of serial measurements of S-100 protein versus neuron-specific enolase (NSE) in blood samples from patients with acute stroke. METHODS Using nonisotopic sandwich immunoassays, we measured plasma concentrations of S-100 protein and NSE on admission and on days 3, 4, 7, and 14 after infarction in 44 patients (age range, 22 to 86 years; mean age, 65.1 years; 12 female, 32 male). Infarct volume was measured by volumetric CT on day 4 after ictus, and clinical outcome was assessed at discharge from hospital with the Activities of Daily Living Scale and 6 months after infarction with the Glasgow Outcome Scale. RESULTS Peak blood levels of S-100 protein were found on day 2.5 +/- 1.3, and peak levels of NSE were found on day 1.9 +/- 0.8 after infarction. Peak plasma levels of S-100 protein correlated well with infarct volume (r = .75, P < .001) and with clinical outcome assessed with the Glasgow Outcome Scale (r = .51, P < .001). Serum levels of NSE correlated with infarct volume (r = .37, P < .05) but not with clinical outcome (r = .18, P > .05). CONCLUSIONS The results of our study indicate that measuring blood concentrations of S-100 protein periodically in the first 10 days after cerebral infarction helps to predict infarct volume and the long-term neurological outcome more accurately than periodic measurements of blood concentrations of NSE.

[1]  J. Garthwaite,et al.  Serum neuron-specific enolase, carnosinase, and their ratio in acute stroke. An enzymatic test for predicting outcome? , 1996, Stroke.

[2]  Y. Kim,et al.  Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. , 1996, Stroke.

[3]  S. Mckinstry,et al.  Serum neurone‐specific enolase as an indicator of stroke volume , 1996, European journal of clinical investigation.

[4]  S. Fulle,et al.  The S-100: A protein family in search of a function , 1995, Progress in Neurobiology.

[5]  H. Reiber,et al.  Neuron‐Specific Enolase Concentrations in Blood as a Prognostic Parameter in Cerebrovascular Diseases , 1994, Stroke.

[6]  F. Barone,et al.  Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia , 1993, Brain Research.

[7]  R. Mckernan,et al.  CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model , 1992, Brain Research.

[8]  R. Donato.  Perspectives in S-100 protein biology. Review article. , 1991, Cell calcium.

[9]  S. Mckinstry,et al.  Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction , 1991, European journal of clinical investigation.

[10]  K. Haglid,et al.  Determination of S‐100 and Glial Fibrillary Acidic Protein Concentrations in Cerebrospinal Fluid After Brain Infarction , 1991, Stroke.

[11]  Y. Olsson,et al.  S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. , 1989, Journal of neurosurgery.

[12]  Y. Olsson,et al.  Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid. , 1988, Stroke.

[13]  H. Hårdemark,et al.  S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. , 1987, Stroke.

[14]  J. Baudier,et al.  Ions binding to S100 proteins. I. Calcium- and zinc-binding properties of bovine brain S100 alpha alpha, S100a (alpha beta), and S100b (beta beta) protein: Zn2+ regulates Ca2+ binding on S100b protein. , 1986, The Journal of biological chemistry.

[15]  M. Noppe,et al.  Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[16]  J. Pujol,et al.  Experimental Brain Ischemia: Neuron‐Specific Enolase Level in Cerebrospinal Fluid as an Index of Neuronal Damage , 1984, Journal of neurochemistry.

[17]  G. Davies-Jones,et al.  Cerebrospinal fluid enolase in stroke. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[18]  Kanefusa Kato,et al.  Nervous system-specific enolase in serum as a marker for neuroblastoma. , 1983, Pediatrics.

[19]  B. Jennett,et al.  ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale , 1975, The Lancet.

[20]  M. Wiesmann,et al.  Measurement of S-100 Protein in Human Blood and Cerebrospinal Fluid: Analytical Method and Preliminary Clinical Results , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[21]  D. Schmechel,et al.  Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. , 1987, Annual review of neuroscience.